Antibiotic Release Articles & Analysis
9 news found
For example, patients whose care requires devices like ventilators or intravenous catheters, and patients who are taking long courses of certain antibiotics are most at risk. “Klebsiella bacteria have increasingly developed antimicrobial resistance, including to the class of antibiotics known as carbapenems,” said Derrick A. ...
The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly finding new ways to avoid the effects of the antibiotics used to treat those infections. Vancomycin-resistant enterococci (VRE) is the name for the bacteria resistant to the antibiotic known as vancomycin. When the CDC released the 2019 ...
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the ...
The company’s lead product in development is called LDGraft, and is a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease. In September 2020, Locate Bio in-licensed multiple late-stage orthobiologics assets from the Royal College of Surgeons in Ireland’s (RCSI) University of Medicine and Health Sciences. ...
CognitOss is a drug-device combination product for the treatment of chronic infections within bone. It has a unique antibiotic release profile, targeting both improvements in the elimination of infection, and the regeneration of bone at the infection site. ...
CognitOss is intended to offer surgeons a single surgical procedure alternative, combining a fully resorbable bone graft with best-in-class bone healing properties and a proprietary dual-phasic release of antibiotics, to initially provide a bolus release at the site of the infection and then prevent re-infection through a further controlled ...
"BARDA has offered strong support in the development of the Selux NGP platform and has led the way in the successful government-private sector collaboration to solve one of the world's toughest health challenges -- antibiotic resistance," said Steve Lufkin, CEO at Selux. "This leadership is especially vital now, as new data indicate the antibiotic resistance ...
Carbapenem-resistant Enterobacteriaceae, also known as CRE, are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. According to new figures released by the Centers for Disease Control and Prevention (CDC), approximately 4% of acute care hospitals and 18% of long-term acute care hospitals in the United States ...